Physician profile
Brian D Kleiber
NPI 1235331570
$84,167.35
in general payments reported to CMS, 2019-2025
14 companies · $503 in 2025
The $503 reported for 2025 was less than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $2,048 · 2021: $8,599 · 2022: $25K · 2023: $16K · 2024: $8,418 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $2,602 · Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,650.00 |
| Travel and Lodging | $2,601.61 |
| Food and Beverage | $1,378.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $69,723.68 | 2019-2025 | Prostep, Ortholoc 3di, Ortholoc 2 Lapifuse |
| Encore Medical, LP | $7,314.16 | 2022 | |
| Trilliant Surgical LLC. | $3,815.33 | 2021 | |
| Elite Orthopedics, LLC | $1,644.28 | 2019-2025 | |
| Arthrex, INC. | $776.12 | 2020 | |
| Paragon 28, INC. | $545.46 | 2020-2021 | |
| Zimmer Biomet Holdings, INC. | $144.08 | 2019-2020 | |
| Novastep INC. | $91.83 | 2025 | Nexis |
| Pacira Therapeutics, INC. | $27.97 | 2019 | |
| Smith+Nephew, INC. | $25.82 | 2025 | Tandem, Journey II |
| Organogenesis INC. | $17.72 | 2021 | |
| Hospira, INC. | $14.36 | 2023 | |
| Medline Industries LP | $13.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kleiber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.